MEDICA 2024 + COMPAMED 2024 International and Diverse Trade Fairs to Welcome Over 6,000 Exhibitors
|
By LabMedica International staff writers Posted on 31 Jul 2024 |

The healthcare business and the medical technology sector are moving dynamically forward, driven by ever-new technical developments. Innovative, digital, and connected this is how the sector defies challenging market and general conditions. Keeping pace with the industry, the MEDICA and COMPAMED trade fairs organized by Messe Düsseldorf (Düsseldorf, Germany) are also holding their own with their combination of globally unique platforms for business and information, serving the entire added value chain of medical-technology systems and products – including manufacturing and development. Based on the exhibitor registration numbers to date, more than 6,000 companies from 70 nations are once again expected to participate at the fairgrounds in Düsseldorf, Germany from November 11 – 14, 2024.
At MEDICA 2024, five worlds of experience promise a comprehensive range of innovations for the treatment of outpatients and clinical use. The worlds of experience are Lab Technology and Diagnostics, Medical Technology and Electromedicine, Commodities and Consumables, Physiotherapy and Orthopedic Technology as well as IT Systems and IT Solutions. Held concurrently with MEDICA again will be COMPAMED which has been a success story for more than thirty years and has developed into an absolute hotspot for complex high-tech solutions. About 750 exhibiting companies will present their specialized knowledge as manufacturers and suppliers at COMPAMED 2024, also in five worlds of experience: Manufacturing & Devices (e.g., components, parts, manufacturing processes), Services & Advice (e.g., research, development, services), Materials (e.g., plastics, glass, ceramics, metals, composite materials, adhesives, packaging), Micro-Tech (such as micro components, microfluidics) as well as IT in Tech (software development and maintenance for medical technology).
Key market trends are currently causing a huge demand for information and many issues for discussion. MEDICA 2024 and COMPAMED 2024 will provide a corresponding top-class stage program with accompanying forums and conferences, offering a connection to the exhibitors’ presentations and topic-driven special exhibitions, such as the ‘Wearable Technologies Show’, the ‘Hospital of the Future’ or the MEDICA SPORTS HUB. This year, the hot topics at MEDICA will include the most recent examples of AI applications robots, and assistive systems in everyday medical practice. Another focus will be on the increasing connectivity in healthcare provision, specifically on innovations for the point of care diagnostics and treatment in proximity of patients (usually outpatients). This also includes telemedical applications to ensure optimal cross-sector collaboration between all those involved in the treatment process.
Another top issue at this year’s MEDICA will be the human factor. Almost all companies active in the healthcare industry are affected by the urgent shortage of skilled workers and are looking for solutions. These will be discussed in a target group-oriented manner in the individual forums and conferences. Examples include the MEDICA HEALTH IT FORUM (on IT topics such as big data, artificial intelligence or cybersecurity), the MEDICA TECH FORUM (trends and topics from science, politics, and business with relevance for the medical technology industry), and the new MEDICA INNOVATION FORUM. This forum will replace the former MEDICA CONNECTED HEALTHCARE FORUM. Because digital innovations are not limited to optimized connections between all healthcare players, the MEDICA INNOVATION FORUM will focus on the digital transformation of the healthcare industry in its entirety. The popular start-up competitions remain part of the program and will highlight fresh ideas and product solutions by the young start-up scene on the forum stage.
COMPAMED 2024 will also be exciting, informative, and open for discussions. The agendas at the COMPAMED HIGH-TECH FORUM and COMPAMED SUPPLIERS FORUM will reflect the top issues of the supply sector such as AI, robotics and automation, new trends in microtechnology, and innovations in materials. There will also be contributions and discussions on best practices in international market development. Supply chain management, product approval issues, and patent law will be relevant aspects of this. Last year, MEDICA and COMPAMED recorded a total of 83,000 visiting professionals from more than 160 countries.
“With a volume of approximately 140 billion euros, the market for medical technology in Europe is extremely important for many of our exhibitors. Regardless of healthcare policy debates, this is equally true for the German market, which alone accounts for 40 billion euros,” said Christian Grosser, Director Health & Medical Technologies at Messe Düsseldorf, explaining why exhibiting companies benefit and also considers the 2024 date to be set with a view to the trade visitors attending. “In order to be fit for tomorrow’s healthcare, it is critical to remain up to date by way of networking, knowledge transfer and innovations at the highest level. MEDICA in Düsseldorf has been providing excellent opportunities to do this for over half a century.”
Related Links:
Messe Düsseldorf
Latest Industry News
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more







